Antiangiogenic Activity and Pharmacogenomics of Medicinal Plants from Traditional Korean Medicine

Figure 6

Docking studies of candidate antiangiogenic compounds. (a) Docking of 6 compounds into the binding site of VEGFR1-TK (PDB code: 3HNG in blue surface representation). The compounds occupy the same binding site as axitinib, a known antiangiogenic compound (in violet). Docked structure of axitinib (b), eriodictyol tetraacetate (c), emodin (d), apigenin (e), verbascoside (f), and resveratrol (g) in VEGFR1-TK binding pocket. The residues involved in hydrogen bond interaction are labeled, and hydrogen bonds are shown as green dots. Axitinib is a known VEGFR-TK inhibitor and was used as control drug.